Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

Gut

Volumn 40, Issue 4, 1997, Pages 470-474

  Bauditz, J ^a   Haemling, J ^b   Ortner, M ^a   Lochs, H ^a   Raedler, A ^b   Schreiber, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Tabea Centre for Inflammatory Bowel Disease   (Germany)

Author keywords

Crohn's disease; Inflammation; Intestinal immunity; Oxpentifylline; Tumour necrosis factor

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 1BETA; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DRUG EFFICACY; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL;

EID: 0030925172     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.4.470     Document Type: Article

References (46)

1. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-β by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn's disease. Gut 1989; 30: 835-8.
2. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease - enhanced production during active disease. Gut 1990; 31: 686-9.
3. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990; 81: 301-5.
4. Schreiber S, MacDermott RP, Raedler A, Pinnau R, Bertovich M, Nash GS. Increased activation of intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 1991; 101: 1020-30.
5. Schreiber S, Heinig T, Panzer U, Reinking R, Bouchard A, Stahl PD, et al. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995; 108: 21-33.
6. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, et al. Tumor necrosis factor-α, interleukin-1β and interleukin 6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37: 818-26.
7. Isaacs KL, Sartor RB, Haeskil JS. Cytokine messenger RNA profiles in inflammatory bowel disease detected by polymerase chain reaction amplification. Gastroenterology 1992; 103: 1587-95.
8. Dinarello CA, Wolff SM. The role of interleukin 1 in disease. N Engl J Med 1993; 328: 106-13.
9. Rampart M, De Smet W, Fiers W, Herman AG. Inflammatory properties of recombinant tumor necrosis in rabbit skin in vivo. J Exp Med 1989; 169: 2227-32.
10. Kindler V, Sappino AP, Gran GE, Piguet PF, Vassali P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-40.
11. Amiri P, Locksley RM, Parslow TG, Sadick M, Rector E, Ritter D, et al. Tumor necrosis factor alpha restores granulomas and induces parasite egg-laying in schistosome-infected SCID mice. Nature 1992; 356: 604-7.
12. Clauss M, Ryan J, Stern D. Modulation of endothelial cell hemostatic properties by TNF: Insights into the role of endothelium in the host response to inflammatory stimuli. In: Beutler B, ed. Tumor necrosis factors: The molecules and their emerging role in medicine. New York: Raven Press, 1992: 49-63.
13. Sun XL, Hsueh W. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest 1988; 81: 1328-31.
14. Mullin JM, Snock KV. Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability. Cancer Res 1990; 50: 2172-6.
15. Deem RL, Shanahan F, Targan SR. Triggered human mucosal T cells release tumor necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells. Clin Exp Immunol 1991; 83: 79-84.
16. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of release tumor necrosis factor-alpha in childhood chronic inflammatory bowel disease, Gut 1991; 32: 913 7.
17. Braegger CP, Nicholls SW, Murch SH, Stephens S, MacDonald TT. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
18. Schreiber S, Koop I, Bauditz J, Nikolaus S, Lochs H. Increased secretion of proinflammatory cytokines by LPMNC is a predictor for relapse of IBD. Gastroenterology 1995; 108: A332.
19. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, et al. Tumor necrosis factor α, interleukin 1β and interleukin 6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37: 818 26.
20. Capello M, Keshav S, Prince C, Jewell DP, Gordon S. Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation. Gut 1992; 33: 1214-9.
21. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455-65.
22. Hyams JS, Treem WR, Eddy E, Wyzga N, Moore RE. Tumor necrosis factor alpha is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991; 12: 233-6.
23. Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G, et al. Tumor-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993; 342: 173-4.
24. van Dullemen HM, van Deventer SJH, Hommes DW, BiJl HA, Jansen J, Tytgat GNJ, Woody J, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric antibody (cA2). Gastroenterology 1995; 109: 129-35.
25. Stack W, Mann S, Roy A, Heath P, Sopwith M, Freeman J, et al. The effects of CDP571, an engineered human IgG4 anti-TNF-alpha antibody in Crohn's disease. Gastroenterology 1996; 110: A1018.
26. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-6.
27. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78: 1205-11.
28. Dezube BJ, Pardee AB, Chapman B, Beckett LA, KorvickJA, Novick WJ, et al. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. Journal of Aquired Immunodeficiency Syndrome 1993; 6: 787-94.
29. Neuner P, Klosner G, Schauer E, Pourmojib N, Macheiner W, Grünwald C, et al. Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumor necrosis factor by human peripheral blood mononuclear cells. Immunology 1994; 83: 262 7.
30. Tilg H, Eibl B, Pichl M, Gächter A, Herold M, Brankova J, et al. Immune response modulation by pentoxifylline in vitro. Transplantation 1993; 56: 196-201.
31. van Leenen D, Vanderpoll T, Levi M, Tencate H, van Deventer SJH, Hack CE, et al. Pentoxifylline attenuates neutrophil activation in experimental endotoxinemia in chimpanzees. J Immunol 1993; 151: 2318-25.
32. Breuillé D, Farge MC, Rosé F, Arnal M, Attaix D, Obled C. Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. Am J Physiol 1993; 265: E660-6.
33. Attal M, Huguet F, Rubie H, Charlet JP, Schlaifer D, Huynh A, et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 1993; 82: 732-6.
34. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor factor synthesis at separate points in the signalling pathway J Exp Med 1990; 172: 391-4.
35. Kovach NL, Lindgren CG, Fefer A, Thompson JA, Yednock T, Harlan JM. Pentoxifylline inhibits integrinmediated adherence of interleukin-2 activated human peripheral blood lymphocytes to human umbilical vein cells, matrix components, and cultured tumor cells. Blood 1994; 84: 2234-42.
36. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern J Jr, et al. National cooperative Crohn's disease Study: Results of drug treatment. Gastroenterology 1979; 77: 847 69.
37. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European cooperative Crohn's disease study (ECCDS): Results of drug treatment. Gastroenterology 1984; 86: 249-66.
38. Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 27-34.
39. GETAID represented by Mary JY and Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective, multicentre study. Gut 1989; 30: 983-9.
40. Reinecker HC, Steften M, Witthöft T, Pflueger I, Schreiber S, MacDermott RP, et al. Enhanced secretion of tumor necrosis factor-alpha, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
41. Sachs L. Angewandte Statistik. 7th ed. Heidelberg: Springer, 1992.
42. Nikolaus S, Hampe J, Bauditz J, Ortner M, Reichelt E, Lochs H, et al. Pivotal role of granulocytes in immunoregulation in inflammatory bowel disease? Gut 1996; 39 (suppl 3): A2.
43. Dinarello CA. Interleukin-1 and tumor necrosis factor and their naturally occuring antagonists during hemodialysis. Kidney Int Suppl 1992; 38: S68-77.
44. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 45-53.
45. Scallon BJ, Moore MA, Trinh DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody, cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7: 251 9.
46. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature 1996; 379: 739-42.